Table 1. Current phase III trials investigating antibodies that target the PD-1/PD-L1,2 pathway.
| Agents | NCI Identifier | Cancer type | Setting | Phase | n | Primary end point |
|---|---|---|---|---|---|---|
| Nivolumab vs Everolimus |
NCT01668784 |
Pre-treated or metastatic RCC |
Pre-treated or first-line |
III |
822 |
Overall survival |
| Nivolumab vs Nivolumab + Ipilimumab vs Ipilumab |
NCT01844505 |
Metastatic melanoma |
First-line |
III |
917 |
Overall survival |
| Nivolumab vs Dacarbazine |
NCT01721772 |
Metastatic melanoma |
First-line |
III |
410 |
Overall survival |
| MK-3475 (2 dose levels) vs Ipilimumab |
NCT01866319 |
Metastatic melanoma |
Pre-treated or first-line |
III |
645 |
Overall survival
Progression-free survival |
| MPDL3208A |
NCT01846416 |
NSCLC
(PDL1+) |
First-line |
II |
130 |
Response rate |
| MPDL3280A vs Docetaxel | NCT01903993 | NSCLC | Platinum pre-treated | II | 180 | Response rate |
Abbreviations: NCI=National Cancer Institute; NSCLC=non-small cell lung cancer; RCC=renal cell carcinoma.